通化金马:新药已进入综合审评环节，审批工作正常进行中

Group 1 - The company confirms that the approval process for its new drug is currently proceeding normally and is in the final stages of comprehensive review [2] - The new drug, Amber Dihydroaminoacridine Tablets, has completed all professional review work and is now in the comprehensive review phase [2] - The company will disclose any significant information as per regulatory requirements if it meets the criteria for information disclosure [2]